FIELD: medicine.
SUBSTANCE: method involves administering pyrimidine nucleotide precursors at a daily dose of 0.05-0.3 g/kg of body weight. The method is applicable under condition that cytotoxic chemotherapy agent does not belong to pyrimidine nucleoside analogs.
EFFECT: enhanced effectiveness in eliminating mitochondrial respiration chain dysfunction.
2 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF MITOCHONDRIAL MALFUNCTIONS | 2000 |
|
RU2394580C2 |
| METHOD FOR TREATING MITOCHONDRIAL DISORDERS | 2000 |
|
RU2268732C2 |
| APPLICATION OF FUMARIC ACID DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | 2000 |
|
RU2218918C1 |
| COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | 2011 |
|
RU2745439C2 |
| COMPOSITIONS FOR TOBACCO ADDICTION TREATMENT AND GETTING RID OF SMOKING HABIT | 2003 |
|
RU2329811C2 |
| COMPOUNDS USED FOR SLEEP/WAKEFULNESS CYCLE NORMALISATION | 2003 |
|
RU2366428C2 |
| COMPOSITIONS AND METHODS FOR IMPROVING OR MAINTAINING MUSCLE PERFORMANCE | 2011 |
|
RU2606763C2 |
| TREATMENT OF MITOCHONDRIAL DISEASES | 2016 |
|
RU2745611C2 |
| LIPID-BASED FORMULATIONS FOR RNA DELIVERY | 2019 |
|
RU2815001C2 |
| DEOXYNUCLEOSIDE THERAPY OF DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS, INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES | 2016 |
|
RU2721492C2 |
